NASDAQ$BBIO
Bridgebio Pharma Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
BridgeBio Pharma reported Q3 2025 a net loss of $123.1M, diluted EPS of $0.95.
For Q3 2025, BridgeBio Pharma reported net loss was $123.1M, diluted EPS was $0.95. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Net loss $123.1M.
- Diluted EPS $0.95.
- MD&A highlights operating priorities, capital, and sector risks.
Headline financials
Revenue & EPS history
Bridgebio · Revenue · Quarterly
$121M
Revenue by segment
Bridgebio · $100K total across 1 segment · Q2 2023
- License and Services Revenue$100K—100.0%
Forward guidance
Biotech and pharma outlook centers on pipeline milestones, launches, and cash runway.
Tailwinds
- Product revenue growth and label expansions.
- Collaboration and trial readouts support the narrative.
Headwinds
- R&D spend and operating losses pressure near-term earnings.
- Regulatory and competitive risks for key products.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+1.5%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+4.3%
Avg return
30 days after
48%
13 / 27 earnings
Positive
+40.9%
Q2 2022
Best reaction
-21.9%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | -3.2% | -0.7% | |
| Q4 2025 | -2.8% | -4.1% | +2.0% | |
| Q3 2025 | -4.9% | -7.9% | +8.1% | |
| Q1 2025 | +5.3% | +4.9% | -6.0% | |
| Q4 2024 | +1.4% | -5.3% | -4.2% | |
| Q3 2024 | -5.1% | -9.2% | +5.9% | |
| Q2 2024 | +0.9% | -4.2% | +7.3% | |
| Q1 2024 | +3.0% | +2.8% | +3.6% | |
| Q4 2023 | -0.5% | +4.6% | -13.4% | |
| Q3 2023 | +8.2% | +10.3% | +16.1% | |
| Q2 2023 | -2.3% | +0.8% | -4.4% | |
| Q1 2023 | -5.0% | -4.4% | -1.0% | |
| Q4 2022 | -4.7% | -6.6% | +21.8% | |
| Q3 2022 | -1.1% | -7.0% | -4.8% | |
| Q2 2022 | +40.9% | +39.7% | +26.7% | |
| Q1 2022 | -21.9% | -29.5% | -15.9% | |
| Q4 2021 | +7.6% | +13.9% | +41.1% | |
| Q3 2021 | +6.8% | +2.0% | -22.8% | |
| Q2 2021 | +2.4% | -1.1% | -2.3% | |
| Q1 2021 | -9.3% | -7.2% | +9.5% | |
| Q4 2020 | +4.9% | -1.8% | -9.8% | |
| Q3 2020 | -1.6% | +0.3% | +30.4% | |
| Q2 2020 | +1.4% | +0.2% | +16.2% | |
| Q1 2020 | -6.8% | +6.1% | -12.7% | |
| Q4 2019 | +2.2% | -9.3% | -21.3% | |
| Q3 2019 | +22.1% | +26.2% | +49.0% | |
| Q2 2019 | +0.0% | +4.8% | -3.2% | |
| Q1 2019 | — | — | — | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro